



July 17, 2025

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051

Symbol: LUPIN

BSE Limited

P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
Mumbai - 400 001

Scrip Code: Equity - 500257

Subject: Disclosure pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')

Dear Sir/Madam,

We would like to notify that the U.S. FDA inspected Lupin's Pithampur Unit-3 manufacturing facility from July 07 to July 17, 2025. The inspection closed with the issuance of a Form-483 with three observations.

We will address the observations and collaborate with the U.S. FDA to resolve them within the stipulated timeframe. We are committed to be compliant with CGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI Listing Regulations.

Thanking you,

For LUPIN LIMITED

**AMIT KUMAR GUPTA
COMPANY SECRETARY & COMPLIANCE OFFICER
(ACS -15754)**

LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

www.lupin.com